Acne has always been of keen interest to me - one of the main reasons I invested in this company years ago - the addressable TAM for Acne is immense and not only does it replace terrible drugs like Roaccutane but it appeals to the vanity market as well.
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-186
Add to My Watchlist
What is My Watchlist?